Last reviewed · How we verify
Investigational live attenuated mumps vaccine
Investigational live attenuated mumps vaccine is a Live attenuated vaccine Biologic drug developed by Sinovac Research and Development Co., Ltd.. It is currently in Phase 3 development for Mumps prevention.
A live attenuated mumps vaccine stimulates the immune system to recognize and protect against mumps virus infection by using a weakened form of the virus.
A live attenuated mumps vaccine stimulates the immune system to recognize and protect against mumps virus infection by using a weakened form of the virus. Used for Mumps prevention.
At a glance
| Generic name | Investigational live attenuated mumps vaccine |
|---|---|
| Sponsor | Sinovac Research and Development Co., Ltd. |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains a live but weakened (attenuated) mumps virus strain that replicates in the body without causing disease. This triggers both cellular and humoral immune responses, generating antibodies and T-cell memory against mumps virus antigens. Upon exposure to wild-type mumps virus, the primed immune system can rapidly neutralize the pathogen and prevent infection or severe disease.
Approved indications
- Mumps prevention
Common side effects
- Fever
- Local injection site reactions (pain, erythema, swelling)
- Parotitis
- Rash
Key clinical trials
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants (PHASE3)
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age (PHASE3)
- Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants (PHASE3)
- Safety Study of ProQuad® rHA in Infants (V221-037) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational live attenuated mumps vaccine CI brief — competitive landscape report
- Investigational live attenuated mumps vaccine updates RSS · CI watch RSS
- Sinovac Research and Development Co., Ltd. portfolio CI
Frequently asked questions about Investigational live attenuated mumps vaccine
What is Investigational live attenuated mumps vaccine?
How does Investigational live attenuated mumps vaccine work?
What is Investigational live attenuated mumps vaccine used for?
Who makes Investigational live attenuated mumps vaccine?
What drug class is Investigational live attenuated mumps vaccine in?
What development phase is Investigational live attenuated mumps vaccine in?
What are the side effects of Investigational live attenuated mumps vaccine?
Related
- Drug class: All Live attenuated vaccine drugs
- Manufacturer: Sinovac Research and Development Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Mumps prevention
- Compare: Investigational live attenuated mumps vaccine vs similar drugs
- Pricing: Investigational live attenuated mumps vaccine cost, discount & access